Ibuprofen and Paracetamol Pharmacokinetic Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

43 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2014-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study was to determine rates of absorption of Ibuprofen and Paracetamol formulations.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Analgesic Effect of Paracetamol, Paracetamol + Codeine, Ibuprofen and Their Combination

NCT00921700

Pain, Postoperative

COMPLETED PHASE4

A Study Comparing Three Formulations of Ibuprofen in Healthy Subjects

NCT02256423

Healthy Volunteer Study

COMPLETED PHASE1

Effect of Ibuprofen, Paracetamol and Their Combination on Radical Oxygen Species (ROS) Production

NCT00921505

Pain

COMPLETED PHASE4

Pharmacokinetic Interaction Between Ibuprofen and Acetaminophen, Tablets Administered Individually or in Combination

NCT05428306

Healthy

COMPLETED PHASE1

To Evaluate the Food Effect and the Absorption Profile of Ibuprofen Modified-Release Tablets 800 mg

NCT05329454

Chronic Pain

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteer Study

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ibuprofen lysine

Group Type EXPERIMENTAL

Ibuprofen Lysine

Intervention Type DRUG

Ibuprofen sodium

Group Type EXPERIMENTAL

Ibuprofen Sodium

Intervention Type DRUG

Ibuprofen liquid capsules

Group Type EXPERIMENTAL

Ibuprofen Liquid Capsules

Intervention Type DRUG

Ibuprofen acid

Group Type ACTIVE_COMPARATOR

Ibuprofen Acid

Intervention Type DRUG

Paracetamol

Group Type ACTIVE_COMPARATOR

Paracetamol

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ibuprofen Acid

Intervention Type DRUG

Ibuprofen Lysine

Intervention Type DRUG

Ibuprofen Sodium

Intervention Type DRUG

Ibuprofen Liquid Capsules

Intervention Type DRUG

Paracetamol

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age: \> 18 to \< 50 years.
2. Sex: Male and female subjects are eligible for entry.
3. Female subject of child bearing potential with a negative pregnancy test at the screening visit and willing to use an effective method of contraception, if applicable
4. Female subject of non-child bearing potential with negative pregnancy test at the screening visit.
5. Male subject willing to use an effective method of contraception.
6. Status: Healthy volunteers with a body mass index of \>18 and \<30 kg/m2.
7. Absence of relevant abnormalities in the clinical examination, ECG, drug and safety analysis.
8. Subjects who have given written informed consent

Exclusion Criteria

1. Pregnant or lactating female subjects.
2. A history of significant disease of any body-system.
3. Any condition that may currently interfere with the absorption, distribution, metabolism or excretion of drugs.
4. A history of allergy or intolerance (including angio-oedema, urticaria, bronchospasm and rhinitis) related to treatment with ibuprofen, aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs), paracetamol, or the excipients of the formulations.
5. A history of peptic or duodenal ulcers or gastro-intestinal bleed or upper gastro-intestinal bleed, or other significant gastro-intestinal disorders.
6. A history of frequent dyspepsia, e.g., heartburn or indigestion.
7. A history of migraine.
8. A history of psychotic illness, attempted suicide or parasuicide.
9. Current smokers and ex-smokers who have smoked within 6 months.
10. A history of drug abuse (including alcohol).
11. High consumption of stimulating drinks
12. Those with positive drugs of abuse screen including alcohol on any occasion throughout the study.
13. Ingestion of a prescribed drug at any time in the 14 days before dosing with study medication (excluding hormonal contraceptives and hormone replacement therapy), or consumption of enzyme inhibitors or inducers during the previous month (such as barbiturates, carbamazepine, erythromycin, phenytoin, etc).
14. Ingestion of an over-the-counter preparation within 7 days before dosing with study medication, including herbal medications, vitamin/fish oil supplements, ibuprofen and other NSAIDs and paracetamol.
15. Donation of blood in quantity in the previous 12 weeks before enrolment into the study
16. Known human immune deficiency virus (HIV) positive status, or a positive viral serology screen.
17. Topical use of ibuprofen within 7 days before dosing with study medication
18. Those previously randomised into this study.
19. Employee at study site.
20. Partner or first degree relative of the investigator.
21. Those with an ibuprofen level \> 10 ng/ml as determined at pre-study screening visit 2 (Part 2 (Pivotal Phase) of the study only).
22. Those who are unwilling to consume gelatin of animal origin (Part 2 (Pivotal Phase) of the study only).
23. Those who have participated in a clinical trial in the previous 12 weeks
24. Those unable in the opinion of the Investigator to comply fully with the study requirements.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes